Roquefort Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ROQ.L research report →
Companywww.roquefortinvest.com
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
- CEO
- Stephen Paul West
- IPO
- 2021
- Employees
- 7
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $155.54K
- P/E
- -0.16
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- -0.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -18.30%
- ROIC
- -17.20%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-971,803 · 44.29%
- EPS
- $-0.07 · 44.44%
- Op Income
- $-1,111,515
- FCF YoY
- 56.16%
Performance & Tape
- 52W High
- $3.00
- 52W Low
- $0.90
- 50D MA
- $1.13
- 200D MA
- $1.52
- Beta
- -0.56
- Avg Volume
- 945.47K
Get TickerSpark's AI analysis on ROQ.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ROQ.L Coverage
We haven't published any research on ROQ.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ROQ.L Report →